secwatch.observer — SEC 8-K summary
======================================

Issuer:     Verona Pharma plc (—)
CIK:        0001657312
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001104659-24-059109
Event type: debt
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 1.02, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Verona Pharma secures up to $650M strategic financing from Oaktree and OMERS for ensifentrine launch
--------------------------------------------------------------------------------

- Debt facility of $400M in five tranches; $55M drawn at close, $70M upon FDA approval, $175M on sales milestones, $100M discretionary.
- Revenue interest agreement (RIPSA) up to $250M; $100M upon FDA approval, $150M on sales milestones; capped at 1.75x funded amount.
- Debt interest 11% p.a., interest-only quarterly, maturity May 2029; exit fee 2.5%; prepayment fees 1-7%.
- Proceeds used to repay $50M prior loan to Oxford/Hercules and for general working capital.
- Existing cash of $255M plus new funding extends cash runway beyond 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1657312/000110465924059109/0001104659-24-059109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1657312/000110465924059109/tm2413907d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-059109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer